KMT2A and myeloproliferative neoplasm: In order to identify ruxolitinib mediated rebound activation of STAT5 target genes induction in MPN patients, we collected RNA-seq data of MPN patients treated with either ruxolitinib or other treatments (non-JAK inhibitor) from the MLL (Münchner Leukämielabor GmbH).